Koninklijke Philips (NYSE:PHG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Koninklijke Philips (NYSE:PHG) has received an average rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company.

A number of research firms recently commented on PHG. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a research report on Thursday, February 20th. Sanford C. Bernstein upgraded Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 18th. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Finally, BNP Paribas upgraded shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research report on Tuesday, February 25th.

Koninklijke Philips Stock Down 0.2 %

Shares of NYSE PHG opened at $25.65 on Friday. Koninklijke Philips has a 52-week low of $19.10 and a 52-week high of $32.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. The business has a fifty day moving average of $26.73 and a two-hundred day moving average of $27.55. The stock has a market cap of $24.10 billion, a PE ratio of -30.53, a PEG ratio of 0.82 and a beta of 0.78.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). The firm had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. As a group, equities research analysts expect that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Koninklijke Philips Cuts Dividend

The company also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be issued a dividend of $0.886 per share. This represents a yield of 2.9%. The ex-dividend date is Tuesday, May 13th. Koninklijke Philips’s dividend payout ratio is -89.29%.

Institutional Investors Weigh In On Koninklijke Philips

Several hedge funds and other institutional investors have recently made changes to their positions in PHG. Colonial Trust Co SC lifted its stake in shares of Koninklijke Philips by 724.0% during the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company’s stock valued at $36,000 after acquiring an additional 1,238 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Koninklijke Philips during the 3rd quarter valued at about $54,000. Farther Finance Advisors LLC lifted its position in Koninklijke Philips by 37.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock valued at $54,000 after purchasing an additional 582 shares during the period. Whipplewood Advisors LLC bought a new position in shares of Koninklijke Philips in the 4th quarter valued at about $55,000. Finally, Millstone Evans Group LLC acquired a new stake in shares of Koninklijke Philips during the 4th quarter worth approximately $60,000. 13.67% of the stock is owned by institutional investors and hedge funds.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.